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Abstract
FPC (fibrocystin or polyductin) is a single transmembrane receptor-like protein, responsible for the human autosomal
recessive polycystic kidney disease (ARPKD). It was recently proposed that FPC undergoes a Notch-like cleavage and
subsequently the cleaved carboxy(C)-terminal fragment translocates to the nucleus. To study the functions of the isolated C-
tail, we expressed the intracellular domain of human FPC (hICD) in renal epithelial cells. By 3-dimensional (3D) tubulogenesis
assay, we found that in contrast to tubule-like structures formed from control cells, hICD-expressing cells exclusively formed
cyst-like structures. By western blotting, we showed that the Akt/mTOR pathway, indicated by increased phosphorylation of
Akt at serine 473 and S6 kinase 1 at threonine 389, was constitutively activated in hICD-expressing cells, similar to that in
FPC knockdown cells and ARPKD kidneys. Moreover, application of mTOR inhibitor rapamycin reduced the size of the cyst-
like structures formed by hICD-expressing cells. Application of either LY294002 or wortmannin inhibited the activation of
both S6K1 and Akt. Expression of full-length FPC inhibited the activation of S6 and S6 kinase whereas co-expression of hICD
with full-length FPC antagonized the inhibitory effect of full-length FPC on mTOR. Taken together, we propose that FPC
modulates the PI3K/Akt/mTOR pathway and the cleaved C-tail regulates the function of the full-length protein.
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Introduction
The most common forms of polycystic kidney disease (PKD) in
humans are autosomal dominant and recessive PKD (ADPKD
and ARPKD). ADPKD is the adult form of the disease, caused by
mutations in either PKD1 or PKD2, the genes respectively
encoding polycystin-1 and polycystin-2 which form a receptor-
channel complex [1,2]. ARPKD is the pediatric form resulting
from mutations in PKHD1, the gene encoding fibrocystin/
polyductin (FPC) [3–5]. FPC is a single transmembrane protein
(4,074 amino acids, aa) with a large extracellular domain (3,859
aa), a single transmembrane segment (23 aa), and a small
intracellular C-tail (hICD, 192 aa). Abnormalities in cell prolifer-
ation, apoptosis, and extracellular matrix (ECM) are among the
features of PKD [1,2]. FPC interacts with polycystin-2, both of
which are localized to the primary cilia of kidney epithelial cells
[6–12] where they participate cellular mechanosensation [11,13].
The C-terminus of FPC has been suggested to harbor an
atypical 25-residue nuclear localization signal sequence and the
cleaved fragment translocates into the nuclei in mIMCD-3 and
MDCK cells [14,15]. An 18-residue sequence at the C-terminus of
FPC was recently identified to be responsible for its ciliary
targeting by transient expression of a series of deletion constructs
in mIMCD-3 cells [16]. However, the functions of the full-length
FPC and its cleaved C-tail remain unknown. In this study, we
report that hICD expression leads to activation of the phospho-
inositide 3-kinase (PI3K)-Akt-mammalian target of rapamycin
(mTOR) pathway and formation of cyst-like structures in 3D
collagen cultures. Furthermore, we show that mTOR inhibitor
rapamycin reduces the sizes of the cyst-like structures formed by
hICD-expressing cells. Our data suggest that FPC modulates the
activities of the PI3K/Akt/mTOR pathway and that the
expression of FPC C-tail may antagonize the function of the
full-length protein and promote cyst formation.
Results
Expression of hICD
We transiently expressed either hICD alone or the intracellular
domain with its preceding transmembrane segment (hTMC) in
HEK293 cells (Figure 1, Figure S1). Two close bands at ,30 kDa
were detected in hTMC-transfected cells. In addition to the
expected upper higher molecular weight one, the lower molecular
weight band had an identical migration pattern to that in hICD-
transfected cells (Figure 1A). This result is consistent with the
finding that hICD can be cleaved from full-length FPC [14,15]
and the size of the cleaved C-tail is similar to that of hICD. In
order to study the function of the cleaved fragment, we established
four mIMCD-3 cell lines stably expressing hICD (Figure 1B, C). In
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in the nuclei of mIMCD-3 cells with some signals in the cytoplasm.
Expression of hICD leads to cystogenesis
Tubulogenesis assay in collagen I gel or Matrigel is commonly
used to mimic the in vivo morphogenesis of kidney tubules. To
explore the role of hICD in tubulogenesis, we cultured hICD-
expressing cells in 3D collagen gels for up to 8 days. Remarkably,
all four mIMCD-3 cell lines stably expressing hICD formed cyst-
like structures (hICD3, 6, 13, 100%; hICD5, ,100%), in striking
contrast to all four empty vector-transfected control cell lines
(CTL1, 2, 3, 4, 100%) which formed tubule-like structures
irrespective of the absence or presence of hepatic growth factor
(HGF) (Figure 2A). To further analyze the cyst-like structures
formed by hICD-expressing cells, we performed in-gel staining of
these structures with antibodies to acetylated a-tubulin and
phalloidin. Confocal microscopy revealed that all cyst-like
structures possessed a central cavity (Figure 2B). All control cells
developed tubule-like structures with primary cilia protruding
towards the lumen (Figure 2B).
Constitutive mTOR activation in hICD-expressing cells
In order to study the mechanism of cystogenesis, we examined
mTOR signaling pathway in hICD-expressing cells. Aberrant
activation of S6 kinase 1 (S6K1), as indicated by phosphorylation
at threonine 389 (S6K1
T389), was observed in hICD-expressing
cells, compared to that in control cells under serum starvation
conditions (Figure 3A). Consistently, S6, the substrate of
S6K1, was phosphorylated at serines 235/236 and 240/244
(S6
S235/236, S240/244). Because both growth factors and amino acids
independently regulate mTOR in a distinct manner and amino
acids regulate mTOR probably through the cytoplasmic Rag
GTPase [17,18], we went on to test the effects of amino acids on
mTOR signal cascade. Compared to that in control cells, amino
Figure 1. Establishment of hICD-expressing stable cells. (A)
Transient expression of hTMC construct in HEK293 cells produced, in
addition to the expected TMC fragment, a band similar in size to the
intracellular domain of FPC. * Ig heavy and light chains. (B) Western
blotting showing the levels of hICD in four mIMCD-3 cell lines stably
expressing hICD (hICD3, 5, 6, 13), along with four empty vector control
cell lines (CTL1, 2, 3, 4). IB, immunoblotting. (C) FPC C-tail was mainly
localized in the nuclei of mIMCD-3 cells (hICD3) compared to the
control cell line (CTL3). IF, immunofluorescence. Scale bar, 5 mm.
doi:10.1371/journal.pone.0095630.g001
Figure 2. FPC C-tail expression caused cystogenesis in 3D
culture. hICD cells from all four cell lines (3, 5, 6, 13), in parallel with
cells from four control lines, were cultured in collagen I gels. All hICD-
expressing lines (3, 6, 13, 100%; 5, ,100%) formed cyst-like structures in
contrast to tubule-like structures formed by control cells. The
representative pictures were presented (A, B). (A) Tubulogenesis of
both control (CTL1, CTL2) and hICD (hICD3, hICD6) cells at 1, 3 and 7
days after seeding in collagen I gels. At day 3 and 7, in contrast to
control cells, which developed tubule-like structures (100%), hICD-
expressing cells formed cyst-like structures (100%). (B) Confocal
microscopy reveals the presence of a lumen in the tubule-like structure
developed from control cells (CTL1, 2) and a central cavity in cyst-like
structures in hICD-expressing cells (CTL3, 6) after 8-day culture. A
segment of a tubule was shown with a higher magnification. HGF was
not used in this experiment. Red, rhodamine phalloidin; green,
acetylated a-tubulin; blue, DAPI.
doi:10.1371/journal.pone.0095630.g002
FPC mTOR
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expressing cells (Figure 3B).
Activation of mTOR signaling in FPC knockdown cells
and ARPKD kidneys
Constitutive S6K1
T389 activation was also found in FPC
knockdown mIMCD-3 cells [13] (Figure 3C) and in kidney tissues
from 3 ARPKD patients (Figure 3D). Because Akt is a key
regulator of mTOR activity, we studied phosphorylation of
Akt
S473 and found that it was constitutively hyperphosphorylated
in hICD-expressing cells (Figure 3A, B). Interestingly we observed
a decrease in 4E-BP1
T37/46 phosphorylation in hICD-expressing
cells compared to control cells (Figure 3A, B). This decrease was
also detected in FPC knockdown cells and in kidney tissues from
patients with ARPKD (Figure 3C, D).
PI3K is responsible for Akt/mTOR activation
To investigate the mechanisms leading to the activation of
mTOR and Akt in hICD-expressing cells, we examined the
activity of PI3K, the major upstream regulator of Akt, using
inhibitors of PI3K (wortmannin and LY294002). As reported [19],
rapamycin completely inhibited S6K1 activity but not Akt
phosphorylation (Figure 4A). Application of either LY294002 or
wortmannin inhibited the activation of both S6K1 and Akt
(Figure 4B, C). Because there was little information on the dosage
of these inhibitors in mIMCD-3 cells, we examined the effects of
different doses of PI3K inhibitors. We found that S6K1 activity in
hICD-expressing cells was highly sensitive to these inhibitors and
the inhibition of pAkt
S473 was correlated with the decrement of
pS6K
T389 (Figure 4D). The inhibitory effects of LY294002 on
S6K1 in hICD-expressing cells remained in the absence of serum
(Figure 4E).
Treatment of mTOR inhibitor rapamycin inhibits cyst
growth
In order to determine whether sustained activation of mTOR
signaling was responsible for abnormal branching morphogenesis
leading to cystogenesis, we applied the mTOR inhibitor rapamy-
cin to hICD-expressing cells cultured in 3D collagen gels. We
found that cyst-like structures became strikingly smaller in treated
hICD-expressing cells than those in non-treated or DMSO-treated
controls (Figure 4F).
Cell proliferation, cell cycle progression, and apoptosis in
hICD-expressing cells
Increased cell proliferation and apoptosis have been regarded as
the pivotal mechanisms of PKD. We therefore examined cell
growth and apoptosis in hICD-expressing cells. The doubling time
of hICD-expressing cells was a little longer than that of controls,
especially when cultured in 1% serum-containing medium
(Figure 5A). We further analyzed the cell cycle profile of these
cells by flow cytometry. After serum withdrawal for 2 days, a large
Figure 3. mTOR activation in hICD-expressing cells and ARPKD kidneys. (A) In contrast to that in control cells, pS6K1
T389, pS6
S235/236,
pS6
S240/244, and pAkt
S473 were activated and p4E-BP1
T37/46 was suppressed in serum-starved hICD-expressing cells (DMEM/F12/0.5% serum for 16 h).
(B) In amino acid-starved hICD-expressing cells, Akt
S473 and S6K1
T389 were hyperphosphorylated compared to those in controls, whereas 4E-BP1
T37/46
was de-phosphorylated. The bar graphs represented the activation of specified proteins expressed as a ratio of the phosphorylation form/total
protein (N=3). (C) In two pairs of FPC knockdown cells (2850S1 and 2141S26), S6K1
T389 was hyperphosphorylated under serum-starved conditions.
The numbers on the Y-axis were arbitrary units of the bands intensity ratio. (D) S6K1
T389 was highly phosphorylated while phosphorylation of 4E-
BP1
T37/46 was reduced in ARPKD kidneys (AR-1, 2, 3), compared to normal controls (CTL-1, -2, -3). Open bars, control cells; filled bars, hICD-expressing
cells. Values were expressed as mean 6 SD. * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0095630.g003
FPC mTOR
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remained in the S-phase, in contrast to the control cells. After
replenishment of 10% serum, the difference between hICD-
expressing and control cells became negligible (Figure 5B). In the
absence of serum, there was an increase of apoptosis in hICD-
expressing cells by flow cytometry (Figure 5C). To confirm these
data, we performed TUNEL assay in the presence and absence of
10% serum. Compared to control cells, there was a significant
increase in apoptosis in hICD-expressing cells especially in serum-
free conditions (Figure 5D).
The cytoplasmic C-tail of FPC antagonizes the inhibitory
effect of full-length FPC on mTOR
To understand the mechanistic action of hICD, we transiently
expressed hICD in a kidney proximal tubule cell line (LLC-PK1)
stably expressing full-length FPC (hFPCL) [12]. We found that
expression of full-length FPC inhibited mTOR signaling exemplified
by reduced activation of S6K1
T389 (Figure 6A, B). A stronger
inhibitory effect of full-length FPC on mTOR was seen on S6
S240/244
activation (Figure 6A, C). Coexpression of hICD with full-length
FPC, however, relieved the inhibitory effects of full-length FPC on
mTOR activation, or even promoted mTOR activation (at 3 mg)
(Figure 6).
Discussion
In this study, we report for the first time that FPC is capable of
modulating the PI3K/Akt/mTOR pathway. Expression of full-
length FPC inhibited the activation of mTOR. Yet overexpression
of FPC C-tail antagonized the function of full-length protein,
leading to the activation of PI3K, Akt and mTOR pathways,
defects in cell cycle progression and cell survival, and cystogenesis.
Activation of the mTOR pathway was confirmed in FPC
knockdown cells and kidneys from human ARPKD patients.
Pharmacological inhibition of PI3K and mTOR partially inhib-
ited cystogenesis, confirming the contribution of PI3K/Akt/
mTOR activation to cystogenesis of hICD-expressing cells.
The cleavage of FPC C-tail has been observed when full-length
FPC is overexpressed [14,15]. We found here that hTMC, the last
225-residue of human FPC which contains 33 amino acids of the
transmembrane domain and 192 residues of the cytoplasmic tail,
was further cleaved and produced a fragment that was similar in
size to the intracellular tail cleaved from the full-length FPC
[14,15]. These data suggest that the large extracellular portion of
FPC is not required for cleavage to occur. Because both the full-
length FPC and the hTMC constructs were expressed in non-
nuclear compartments of the cell, the cleavage of the FPC C-tail
likely occurred in the cytoplasm or on the cell membrane by an
unidentified enzyme(s). FPC is detected on the primary cilia with
Figure 4. mTOR activation in hICD-expressing cells can be blocked by PI3K inhibitors and rapamycin. (A) Application of rapamycin
completely blocked S6K1
T389 phosphorylation in both hICD-expressing and control cells, while the phosphorylation of Akt
S473 was not affected as
expected. (B, C) PI3K inhibitors LY294002 and Wortmannin displayed inhibitory effects on both pAkt
S473 and pS6K1
T389. (D) The activation of both
pAkt
S473 and pS6K1
T389 were sensitive to a variety of concentrations of wortmannin and LY294002. Short- and long-time exposure of western blotting
was displayed. (E) In the absence of serum, pS6K1
T389 was de-phosphorylated with LY294002 treatment in both control and hICD-expressing cells. (F)
Effects of mTOR inhibitor rapamycin treatment in 3D collagen gels. Cysts were smaller after 11-day treatment of rapamycin (10 nM), in contrast to
vehicle (DMSO)-treated or non-treated ones. Scale bar, 50 mm. Values were expressed as mean 6 SE. *** p,0.001.
doi:10.1371/journal.pone.0095630.g004
FPC mTOR
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believe that FPC undergoes a C-tail cleavage under defined
conditions and some of the cleaved fragments translocate into the
nucleus [14,15]. Notably, our human free FPC C-tail was not
found on the primary cilia, in contrast to the mouse FPC C-tail
constructs used for the study of ciliary targeting sequence
which contains additional nine residues (LSCLVCCWF) in the
transmembrane segment of FPC [16], although nuclear FPC C-
tail signals were also observed in that study [16].
Sustained phosphorylation of S6K1 and S6 in hICD-expressing
cells implied the activation of mTOR signaling pathway. The
mTOR signaling pathway has, in the past several years, gained
much attention in the PKD research field. It was reported that
mTOR is activated in cyst-lining cells in human ADPKD kidneys
and inhibition of mTOR pathway reverses renal cystogenesis in
Figure 5. Decreased cell proliferation rate and increased apoptosis in hICD-expressing cells. (A) The number of hICD-expressing cells was
significantly lower than that of control cells when cultured in 1% but not in 10% serum-containing medium (N=3 hICD3, 6, 13). One representative of
three experiments was presented. (B) With flow cytometry analysis, more hICD-expressing cells passed the restriction point in G1/0-phase but were
arrested in S-phase after serum removal for 48 h. Addition of 10% serum for 24 h completely compromised the effect of hICD expression on the cell
cycle profile (N=3 hICD3, 6, 13). One representative of three experiments was presented. (C) More apoptotic hICD-expressing cells were found in the
absence of serum by flow cytometry analysis (N=3 hICD3, 6, 13). One representative of at least three experiments was presented. (D) Three control
and three hICD cell lines were used for this experiment. Pictures from two control and hICD cell lines were presented. TUNEL staining assay confirmed
an increase of apoptotic hICD-expressing cells. Bar graph represented statistical significance (N=200 cells from three controls and hICD cell lines).
Open bars, control cells; filled bars, hICD-expressing cells. Values were expressed as mean 6 SD. * p,0.05, ** p,0.01, *** p,0.001. Scale bar, 10 mm.
doi:10.1371/journal.pone.0095630.g005
FPC mTOR
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human ADPKD patients were disappointing [21]. The mTOR
protein binds to other proteins to form a rapamycin-sensitive
complex (mTORC1) or a rapamycin-insensitive complex
(mTORC2) [19,22]. The mTORC1 is regulated by upstream
factors such as nutrients, growth factors, and energy metabolism,
and can phosphorylate a series of downstream substrates.
Upstream regulators of mTOR include Akt (PKB), PI3K/PTEN,
TSC1/2, AMPK, and Rheb [23,24]. The mTORC2 has been
suggested to mainly regulate the actin cytoskeleton through Rho
family of small GTPases and protein kinase C [25]. In our
experiments, we found that mTOR activation was associated with
constitutive phosphorylation of Akt
S473. As Akt
S473 is phosphor-
ylated by mTORC2 [26–28], we assumed that Akt
S473 phosphor-
ylated by mTORC2 further activated mTORC1. Together with
the data from the application of PI3K inhibitors, these data
suggest that hICD may activate mTORC1 through PI3K-Akt or
mTORC2-Akt pathways.
We found that the full-length FPC inhibited mTOR activity,
which was consistent with our finding on the aberrant mTOR
activation in FPC knockdown cells and kidney samples from
ARPKD patients. Overexpression of free FPC C-tail antagonized
the full-length protein function and led to mTOR activation. The
mechanisms by which full-length FPC and free C-tail regulated
mTOR activity may be different, as the C-tail was largely located
in the nucleus while the full-length was mostly membrane-
associated. Overexpression of FPC C-tail may disrupt the full-
length FPC mediated signaling pathways by competitively
occupying the binding sites of its interacting proteins, or
sequestering respective proteins into the nucleus and consequently
affecting the physiological function of full-length FPC. When
expressed at a high level, FPC-C-tail overexpression may activate
mTOR through an additional mechanism(s). We cannot exclude
the possibility that hICD activated the mTOR signaling pathway
through a gain-of-function mechanism in the cell nucleus. Because
the level of endogenously cleaved FPC C-tail is, like that of Notch,
too low to be detectible [14], we propose that under normal
physiologically conditions, full-length FPC inhibits mTOR signal-
ing, whereas C-tail cleavage is facilitated under specific conditions.
FPC C-tail-expressing cells exclusively formed cyst-like struc-
tures, suggesting that the consequence of hICD expression is
similar to that of FPC knockdown [29]. Application of mTOR
inhibitor rapamycin reduced the size of cyst-like structures formed
by hICD expressing cells, which indicates that the mTOR
signaling pathway is a potential therapeutic target for ARPKD.
It is generally believed that cyst-lining cells are more prolifer-
ative based on markers such as proliferative cell nuclear antigen.
Indeed, under low serum conditions, we found that, compared to
control cells, there were more C-tail-expressing cells situated in the
S phase of the cell cycle, and fewer cells in the G0/G1 phase,
indicating that FPC regulates G1-S progression. We have
previously shown that FPC regulates centrosome duplication and
mitotic spindle assembly during cell division [12]. Here we found
that the expression of hICD was associated with an increase in
apoptosis, a feature of ARPKD [30] and FPC knockdown cells
[29]. Taken together, the increased apoptosis may be a
consequence of defects in the cell cycle and constitutive activation
of mTOR, as mTOR pathway can either inhibit or promote
apoptosis depending on the cell context [31].
In summary, we show here that ARPKD protein FPC regulated
PI3K/Akt/mTOR signaling pathway. Further research is needed
to understand how FPC and other PKD proteins regulate this
signaling pathway in a coordinated manner.
Materials and Methods
Antibodies
Antibodies to a number of proteins in the mTOR pathway
(pS6K1
T389, S6K1, pS6
S235/236, pS6
S240/244, S6, p4E-BP1
T37/46,
4E-BP1, pAkt
S473, Akt) were obtained from Cell Signaling
Technologies (Cambridge, MA, USA). b-actin and acetylated a-
tubulin antibodies were bought from Sigma (St. Louis, MO, USA).
Antibodies to c-myc (9E10) were purchased from the BWH-BRI
Core Facility. Rhodamine phalloidin was from Invitrogen
(Carlsbad, CA, USA).
DNA constructs, stable cell lines and cell culture
The hICD construct containing the intracellular domain of
human FPC (192 aa) was described previously [9]. The hTMC
construct containing the human FPC C-terminal 225 aa was made
by RT-PCR and cloned into pcDNA4 at Hind III/Xba I sites
(Figure S1). For the establishment of stable cell lines, hICD
Figure 6. Opposite roles of full-length FPC and C-tail on mTOR. (A) Human full-length FPC- (hFPCL)- and control empty vector (P4L)-
expressing LLC-PK1 cells were transfected with various amounts of hICD plasmid DNA (0, 1, 3 mg). Twenty-four hours after transfection, cells were
serum starved for 24 h before protein extraction. Expression of full-length FPC inhibited the phosphorylation of p70S6K
T389 and pS6
S240/244 in
comparison to the controls, while hICD expression antagonized the inhibition of full-length FPC on p70S6K
T389 and pS6
S240/244 in a dose-dependent
fashion. One representative experiment was shown.
doi:10.1371/journal.pone.0095630.g006
FPC mTOR
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Madison, WI, USA) into mIMCD-3 cells (ATCC, Bethesda, MD,
USA) cultured in DMEM/F12 media (Cellgro, Manassas, VA,
USA), supplemented with 10% FBS (Invitrogen), and screened for
cells resistant to Zeocin (Invitrogen, 750 mg/ml). For amino acid
deprivation condition, cells were serum-starved for 16 h and then
cultured in DMEM/F12 media without amino acids for 30 min.
For drug treatments, stable cells were incubated with culture
media containing appropriate chemical reagents for a period of
time as specified in the Results. FPC knockdown cells were
described previously [13]. Different amounts of hICD expression
construct DNA were transiently transfected into LLC-PK1 cells
stably expressing full-length FPC or empty vector control cells P4L
[12]. Two days after transfection, cells were harvested for western
blotting analyses.
Immunostaining
The method for immunostaning was described in detail
previously [13]. In brief, cultured cells were fixed with 3%
paraformaldehyde (Sigma)/2% sucrose (Sigma) and permeabilized
with 0.1% Triton X-100 (Sigma). After incubation with primary
antibodies for 1 h, cells were incubated with secondary antibodies
Alexa Fluor 488 and/or 594 (Invitrogen) for another hour. Nuclei
were stained with DAPI (49-6-diamidino-2-phenylindole) (Sigma).
A Zeiss Axioskop2 Plus fluorescence microscope (Carl Zeiss Inc.,
Thornwood, NJ, USA) and the Spot camera system (Diagnostic
Instruments, Sterling Heights, MI, USA) were used for epifluor-
escence analysis.
Protein extraction, co-immunoprecipitation, and
immunoblotting
Proteins were extracted with M-PER Mammalian Extraction
Reagent (Pierce, Rockford, IL, USA) or RIPA lysis buffer
(Upstate, Waltham, MA, USA) according to the protocol provided
by the company. For immunoprecipitation, the supernatants were
precleared with protein A/G agarose beads (Pierce; Invitrogen) for
1ha t+4uC before addition of the primary antibody. Subsequent-
ly, agarose beads and the antibody were added and incubated at
+4uC for 4–24 h, followed by centrifugation at 10,000 g for 1 min
at +4uC. The beads were washed twice with the lysis buffer.
Finally, 50 ml of Laemmli’s SDS-Sample buffer (Boston BioProd-
ucts, Ashland, MA, USA) was added. The protein samples were
electrophoresed in a 5%–12% acrylamide Laemmli resolving gel
and transferred to Hybond ECL nitrocellulose membranes (GE
Healthcare, Boston, MA, USA). After blocking with 5% non-fat
dry milk (Bio-Rad, Hercules, CA, USA) in PBS, the filter was
incubated with the primary antibody and washed with PBS/0.1%
Tween 20 (Bio-Rad). The filters were finally incubated with
secondary immunoglobulins conjugated with HRP (GE Health-
care). The bound antibodies were detected with the Detection
Reagent (Pierce). Restore Western Blot Stripping Buffer (Pierce)
was used according to the protocol provided by Pierce to strip the
membrane, prior to reblotting with another antibody. Quantifi-
cation of the band intensity was accomplished with NIH Image J
software. Human kidney samples were gifts from Dr. P. Wilson.
The ages of three ARPKD patients were 2 years, 1 month and 9
days, and three normal controls were 2 years, 15 months and 2
months, respectively. These samples had been published previ-
ously [32].
Cell growth curve and flow cytometry
Cells were trypsinized, pelleted, and resuspended in 5 ml of
culture medium, followed by seeding in 10 cm dishes with a
density of ,50,000 cells per dish. Cells were stained with
tryptophan blue (Invitrogen) and counted with a hemocytometer
daily for a total of 9 days. Cells in the culture media were also
counted and included. Cell cycle analysis was performed with flow
cytometry (BD FACSCanto
TM benchtop flow cytometer, Franklin
Lakes, NJ, USA). For cell synchronization, cells were cultured in
medium without FBS for 48 h, followed by addition of 10% FBS
for 24 h. Before flow cytometry, cells were stained with propidium
iodide (Invitrogen)/Triton X-100 staining solution with RNase A
(Invitrogen) for 30 min at room temperature.
Apoptosis assay
Apoptosis was evaluated with flow cytometry and TUNEL
staining. TUNEL staining was done according to the protocol
provided by Roche (In Situ Cell Death Detection Kit). Briefly, cells
cultured on the plates were fixed with 3% paraformaldehyde with
2% sucrose for 10 min, followed by complete washing. Before
TUNEL reaction mixture was added, cells were permeabilized
with Triton X-100. Samples were analyzed by fluorescence
microscopy as described above.
Tubulogenesis assay in 3D collagen gels and confocal
microscopy [33,34]
Tubulogenesis was performed in PureCol gels (Sigma). Cells
were trypsinized and resuspended in 1 ml of DMEM/F12
medium. Five to ten microliter of single suspension (,4610
4
cells) was well mixed with 850 ml of collagen solution (collagen
type I, 106 DMEM (Sigma), HEPES (Sigma) at 8:1:1 ratio).
Hepatocyte growth factor (Sigma) was added into the solution
before seeding (0.5 mg/ml) or into the culture medium in some
experiments. Collagen solution was poured into a 6-well plate for
1–2 h for solidification followed by addition of DMEM/F12/10%
FBS medium. Cells were allowed to grow in a collagen gel for up
to 8 days before staining. For confocal microscopy analysis, the gel
was first incubated with 16 collagenase (Sigma) for 10 min at
37uC before fixation with 3% PFA for 30 min, followed by
addition of the quench solution (0.7 M NH4Cl and glycine in PBS)
for 10 min. After washing, acetylated a-tubulin antibody
(1:10,000) in PFS (14% fish skin gelatin and 0.2% saponin in
PBS) was incubated with the gel overnight at +4uC. FITC-labeled
secondary antibody and rhodamine phalloidin (1:250) (Invitrogen)
were incubated with the gel for 1 h at room temperature. Before
mounting, the gel was incubated again with 3% PFA for 15–
20 min, followed by washing and DAPI staining procedures.
Confocal images were captured with Nikon microscopy (eclipse
80i) and analyzed with software EZ-C1 (3.91).
Statistics
Values were expressed as mean 6 standard deviation (SD) or
standard error (SE). Student’s T-Test and Chi-Square Test were
used. Spearman correlation was used to calculate the correlation
coefficient of time and hICD expression level. p,0.05 was
considered statistically significant.
Supporting Information
Figure S1 Schematic structure of the human FPC C-tail
construct used in this study. Top, scheme of human full-
length FPC which encodes a 4,074-aa protein with a large
extracellular domain, a single transmembrane domain (red box),
and a 192-aa intracellular fragment; Middle, human FPC C-tail
hICD construct which contains the entire 192-aa intracellular
domain and a 9-aa myc-tag (red oval). Bottom, mouse C-tail [Ref.
FPC mTOR
PLOS ONE | www.plosone.org 7 May 2014 | Volume 9 | Issue 5 | e9563016] is shown for comparison. Green letters, partial or entire ciliary
localization signal; Blue box, nuclear localization signal.
(TIF)
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